Summation of Toxicity Data in Vitic Andrew Thresher

Slides:



Advertisements
Similar presentations
Analysis of High-Throughput Screening Data C371 Fall 2004.
Advertisements

Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)
DECISION TREES. Decision trees  One possible representation for hypotheses.
TRP Chapter Chapter 2.3 Environmental impacts and health risks.
Development of an Institutional Knowledge-base at FDA’s Center for Food Safety and Applied Nutrition Kirk B. Arvidson 1, Annette McCarthy 1, Chihae Yang.
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
Kentucky Division for Air Quality Taimur Shaikh Ph.D.
Batch Reworking and Reprocessing
Establish Verification Procedures (Task 11 / Principle 6)
EPA Tier I Screening Process and
ICASAS305A Provide Advice to Clients
© Tally Solutions Pvt. Ltd. All Rights Reserved 1 Stock Audit in Shoper 9 February 2010.
ADDITIONAL TESTS Ignition Propensity Testing Toxicity Assays.
NSF/ANSI STANDARD 61 FRAMEWORK FOR RISK ASSESSMENTS For use by Toxicology Sub-committee only Please do not copy or distribute.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Characterizing Chemical in Commerce: Using Data on High Production Volume (HPV) Chemicals December 12, 2006 L. Twerdok, Ph.D, DABT NPPTAC Member Report.
CVM’s Procedure for Setting Tolerances
Regulatory Procedure for the Assessment of GM Foods.
Nanotechnology Summary. Potential Worker Exposures.
ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,
Prevalidation Study Plan for Sliced Testes Assay Gary Timm Presented to EDMVS August 20, 2003.
GHS CLASSIFICATION ONLINE. Registration: Click on “Register”
Examining Bioaccumulation & Biomagnification: Implications for Ecosystems and Human Health.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Respiratory Safety Pharmacology Endpoints in Toxicology Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North.
Shri Vaishnav SM Institute of Management, Indore Department of Computer Science Minor Project : MCA 406 ( ) App For Transportation Presented by:
Forging Partnerships on Emerging Contaminants November 2, 2005 John Vandenberg Associate Director for Health National Center for Environmental Assessment.
Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Lhasa ICH M7 Database – Use Cases Dr Angela White.
CALIFORNIA proposed SAFER CONSUMER PRODUCT REGULATIONS Marjorie MartzEmerson October 24, 2012.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
Prof. Dr. Wolfgang Dekant Department of Toxicology University of Würzburg Germany Risk, Hazard, and Innovation.
Balanced Search Trees Problem: Efficiency of BST is related to tree’s height.  search, insert and remove follow a path from root to desired location 
SCOEL and Carcinogens Group A: Non-threshold genotoxic carcinogens; for risk low-dose assessment the linear non-threshold (LNT) model appears appropriate.
Background on Furan in Foods Nega Beru, Ph.D. Director, Division of Plant Product Safety Office of Plant and Dairy Foods Center for Food and Applied Nutrition.
Kamala Pant, M.S. BioReliance Study Director/Principal Scientist
Copyright 2003 Lynn Frock & Company. All Rights Reserved. 1 Five Ways to Build a Microsoft Project Schedule Lynn Frock, PMP Phone
Predictive safety study of ticagrelor's degradation combining LC-MS and in silico approach H. SADOU YAYE*, B. DO, N. YAGOUBI * Pharmacist at Pitié-Salpêtrière.
Environmental Health and Toxicology
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Comparability Protocols Lore Fields MT(ASCP)SBB Consumer Safety Officer DBA/OBRR/CBER September 16, 2009.
Software Engineering Lecture # 1.
An Overview of the Objectives, Approach, and Components of ComET™ Mr. Paul Price The LifeLine Group All slides and material Copyright protected.
International Atomic Energy Agency Regulatory Review of Safety Cases for Radioactive Waste Disposal Facilities David G Bennett 7 April 2014.
Prioritization Process and Development of the Hazard Characterization Documents Office of Pollution Prevention and Toxics U.S. Environmental Protection.
RISK DUE TO AIR POLLUTANTS
Session VII WEIGHING IN ON MICROBIOLOGICAL ADI: EXPERIENCES AND PERSPECTIVES Introduction October 26, 2012.
Role of VICH and VICH guidelines in the approval process for veterinary medicinal products David Mackay, European Medicines Agency VICH Workshop – Dar.
James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.
1 From Regulatory Intelligence to Compliance Debbie Henderson Head, Global Regulatory Policy EU Ring May 13, 2014.
Heavy Metals: Regulatory Aspects DIA-SIG RA-CMC working group 15Mar12 Anders Neil Principal Consultant PAREXEL Consulting.
Classification. Hazard Classification The GHS is designed to identify and classify the “hazards” of the substances or mixtures, and to communicate those.
TOPRA Annual Veterinary Symposium Introduction to the Case Study A presentation by Lesley Reeve, Module leader.
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
QSAR Toolbox Customized search (Query Tool)
Using Derek Nexus to assess the safety of raw materials used in cosmetics and as part of a skin sensitisation ITS. Part 1: Using Derek Nexus to assess.
QSAR Toolbox Customized search (Query Tool)
Software Requirements analysis & specifications
OECD QSAR Toolbox v.4.2 An example illustrating RAAF Scenario 2 and related assessment elements.
InfoCards – making informaiton on chemicals more accessible
QSAR Toolbox Customized search (Query Tool)
QSAR Toolbox Customized search (Query Tool)
The Category Approach for Predicting Mutagenicity and Carcinogenicity
GL18 (R) – Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substance and Excipients.
Quality guidelines on impurities
CEng progression through the IOM3
Guideline for Elemental Impurities ICH Q3D(R)
Presentation transcript:

Summation of Toxicity Data in Vitic Andrew Thresher

Contents Introduction Our solution It’s design It’s implementation The next step

INTRODUCTION

Introduction Large quantity of data are being continuously generated, covering a variety of endpoints and assay protocols. Data may be required for differing uses, for example modelling, regulatory submissions, etc. How can we efficiently access this information in an appropriate manner?

Introduction The ICH M7 guideline states “Hazard assessment involves an initial analysis of actual and potential impurities by conducting database and literature searches for carcinogenicity and bacterial mutagenicity data…” ICH Harmonised Tripartite Guideline Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 2014

Introduction The Vitic database (v ) contains 134,367 bacterial mutagenicity records covering 7,992 compounds. To manually review all data for each compound is time- consuming and open to inter-individual variations in interpretation. To goal was to devise an automated process which would distil the database to allow efficient access to the data.

OUR SOLUTION

Our Solution: Step 1- Subsets First the data is divided into subsets by grouping experiments according to which variables are likely to affect the result. Bacterial strain Absence/presence of metabolic activation. How to balance sufficiently detailed subsets against maintaining robust subset size?

Our Solution: Step 2- Subset Calls Once the subsets have been defined the data is condensed to a single subset call according to the below rules: Results Present Subset Call PositiveEquivocalNegative X Positive X Equivocal X Negative XX Positive X X Conflicted XX XXX

Our Solution: Step 3- Summary Calls These subset calls are then combined to give a single summary call for each test compound. The summary call is given as the highest priority subset call present, where; Positive > Conflicted > Equivocal > Negative

Implementation Ames test 2980 positive, 937 conflicted, 33 equivocal and 3278 negative summary call generated. Chromosome aberration test Subsets based on metabolic activation (with/without) and duration of exposure positive, 66 conflicted, 68 equivocal and 958 negative summary calls generated.

Implementation

Implemenation Local lymph node assay Not split into subsets. EC 3 values calculated. a Median EC 3 calculated for each substance. Potency classifications assigned. b Summary call derived using the subset call rules, removing negative results where the highest tested dose was lower than the median EC 3. a Basketter et.al. Journal of Applied Toxicology (1999) 19, b Loveless et.al. Regulatory Toxicology and Pharmacology (2010) 56, 54-66

Implementation Local lymph node assay 848 positive, 72 conflicted, 4 equivocal and 730 negative summary calls generated. 698 median EC 3 values calculated.

Implementation

THE NEXT STEP

The Next Step Gather user feedback Conflicted calls Can we determine common traits which can be incorporated into the automated workflow? Expansion Can this method be applied to other test types?